Related Experiment Video

Updated: May 25, 2025

Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo
10:35

Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo

Published on: April 6, 2022

2.7K

Advances in sodium-glucose transporter protein 2 inhibitors and tumors

Jiaqi Wang1, Wenyong Yang2

  • 1Department of Oncology, Guangyuan Central Hospital, Guangyuan, Sichuan, China.

Frontiers in Oncology
|February 26, 2025
PubMed

Insights

Sodium-glucose transporter protein 2 (SGLT2) inhibitors show promise as a novel cancer therapy. Overexpressed in tumors, SGLT2 inhibitors may offer new treatment strategies for various cancers.

Area of Science:

  • Oncology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Tumors pose a significant global health challenge with high malignancy and poor prognosis.
  • Current treatments like targeted therapy and immunotherapy have limitations, necessitating novel therapeutic tools.
  • Sodium-glucose transporter protein 2 (SGLT2) inhibitors are established drugs for glycemic control, known for weight reduction and cardioprotective/renoprotective effects.

Purpose of the Study:

  • To comprehensively review the research progress of SGLT2 inhibitors in various tumor types.
  • To integrate the latest studies on SGLT2 inhibitors' role in oncology.
  • To encourage further clinical trials exploring SGLT2 inhibitors for cancer therapy.

Main Methods:

  • Literature review integrating recent studies on SGLT2 inhibitors and cancer.
  • Analysis of SGLT2 overexpression in different tumor types.
  • Evaluation of SGLT2's involvement in tumorigenesis, progression, and metastasis.

Main Results:

  • SGLT2 is overexpressed in numerous tumors.
  • SGLT2 plays a role in cancer development, progression, and metastasis.
  • SGLT2 inhibitors demonstrate potential therapeutic applications across diverse cancers.

Conclusions:

  • SGLT2 inhibitors represent a promising avenue for cancer treatment.
  • Further research and clinical trials are warranted to explore SGLT2 inhibitors' full potential in oncology.
  • This research could lead to improved management strategies and outcomes for cancer patients.
Keywords:
SGLT2icancercarcinogenicitychemotherapy side effectsdiabetic

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.5K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.0K

Related Concept Videos

Secondary Active Transport01:32

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
6.8K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
152
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.4K
Glucose Absorption Into the Small Intestine01:26

Glucose Absorption Into the Small Intestine

Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.2K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
291
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
180